3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Small Cell Lung Carcinoma
4
Nasopharyngeal Carcinoma
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Solid Tumors
1
Recurrence
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma, Adenoid Cystic
1
Interventions
fludarabine
2
durvalumab
2
Cyclophosphamide
2
ruxolitinib
1
repotrectinib
1
ponatinib
1
pembrolizumab
1
gilteritinib
1
fludarabine phosphate
1
cemiplimab
1
atezolizumab
1
Whole-Body Irradiation
1
Tacrolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Immunotherapy
1
Idarubicin
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Cytarabine
1
Cisplatin
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
anlotinib
×
90 days
×
Clear all
No trials found.